A detailed history of Eagle Bay Advisors LLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Eagle Bay Advisors LLC holds 11,200 shares of LYEL stock, worth $6,608. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,200
Holding current value
$6,608
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 13, 2025

BUY
$0.59 - $1.48 $6,608 - $16,576
11,200 New
11,200 $7,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $146M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Eagle Bay Advisors LLC Portfolio

Follow Eagle Bay Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eagle Bay Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eagle Bay Advisors LLC with notifications on news.